Nalaganje...
Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
Once initiated for pulmonary arterial hypertension (PAH), epoprostenol treatment usually needs to be delivered for an indefinite duration. It is possible that some participants could be transitioned from epoprostenol to oral therapies. We retrospectively evaluated eight PAH participants transitioned...
Shranjeno v:
| izdano v: | Pulm Circ |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
SAGE Publications
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5467933/ https://ncbi.nlm.nih.gov/pubmed/28597752 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2045893217702401 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|